Alembic Hits1-Month High on USFDA Recognition for Tenalisib | CORPORATE ETHOS

Alembic Hits1-Month High on USFDA Recognition for Tenalisib

By: | December 26, 2017
alembic

Dec 26: Rhizen Pharmaceuticals SA,  an associate company of drug maker Alembic Pharmaceuticals Ltd, on Tuesday said that the US Food and Drug Administration (USFDA) has granted orphan-drug designation for the active moiety of Tenalisib (RP6530), the company’s highly selective and orally  active dual PI3K delta/gamma inhibitor, for the treatment of peripheral T-cell lymphoma (PTCL).

“We are pleased to receive USFDA orphan-drug designation for the active moiety of Tenalisib, our company’s highly selective and orally active dual PI3K delta/gamma inhibitor and we look forward to advancing the drug into further development for treatment of peripheral T-cell lymphoma (PTCL),” said Swaroop Vakkalanka, Founder & President, Rhizen Pharmaceuticals SA.

Shares of the company surged nearly 1% to touch a new one month high of Rs 535 on BSE in morning trade today. At 10.45 am, the Rs 2 face value shares were trading at Rs 530.30, up 0.18% from the previous closing of Rs 529.35.v